References
1. Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am 2015;44:97–111.
2. Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006;24:59–69.
3. Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013;10:473–486.
4. Kasirer MY, Welsh C, Pan J, Shifrin Y, Belik J. Metoclopramide does not increase gastric muscle contractility in newborn rats. Am J Physiol Gastrointest Liver Physiol 2014;306:G439–G444.
5. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379–390.
6. Gudsoorkar V, Quigley EMM. Choosing a prokinetic for your patient beyond metoclopramide. Am J Gastroenterol 2020;115:5–8.
7. Weihrauch TR, Förster CF, Krieglstein J. Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgrad Med J 1979;55 Suppl 1:7–10.
8. Valenzuela JE. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology 1976;71:1019–1022.
9. Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol 2019;13:711–721.
10. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036–2045.
11. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci 1979;24:662–666.
12. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 1982;96:444–446.
13. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463–467.
14. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985;7:25–32.
15. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:1511–1514.
16. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230–1234.
17. McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984;79:165–172.
18. O'Brien ME, Cullen MH, Woodroffe C, et al. The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial. Br J Cancer 1989;60:759–763.
19. Wilson EB, Bass CS, Abrameit W, Roberson R, Smith RW. Metoclopramide versus ondansetron in prophylaxis of nausea and vomiting for laparoscopic cholecystectomy. Am J Surg 2001;181:138–141.
20. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983;25:451–494.
21. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11–19.
22. Camilleri M. Beyond metoclopramide for gastroparesis. Clin Gastroenterol Hepatol 2022;20:19–24.
23. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689–696.
24. Duan LP, Zheng ZT, Li YN. A study of gastric emptying in non-ulcer dyspepsia using a new ultrasonographic method. Scand J Gastroenterol 1993;28:355–360.
25. Xiang Z, Ma H, Mou Y, Xu CF. Association between polymorphism of dopamine D2 receptor genes and therapeutic effect of domperidone in functional dyspepsia. Turk J Gastroenterol 2015;26:1–5.
26. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429–440.
27. Baeyens R, van de Velde E, De Schepper A, Wollaert F, Reyntjens A. Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine. Postgrad Med J 1979;55 Suppl 1:19–23.
28. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJ. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1–9.
29. Sakamoto Y, Kato S, Sekino Y, et al. Effects of domperidone on gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system). Hepatogastroenterology 2011;58:637–641.
30. Markey O, Shafat A. Does domperidone, a D2-antagonist alter gastric emptying rates and appetite sensations in healthy adults with high-fat meal? A block-randomised, single-blind placebo-controlled study. Ir J Med Sci 2012;181:215–219.
31. Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013;108:1382–1391.
32. Esseboom EU, Rojer RA, Borm JJ, Statius van Eps LW. Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med 1995;47:12–17.
33. van Leeuwen L, Helmers JH. The efficacy of Domperidone (R 33812) in the treatment of postoperative vomiting. A double-blind study with a placebo. Anaesthesist 1980;29:490–493.
34. Nishikawa N, Nagai M, Tsujii T, Iwaki H, Yabe H, Nomoto M. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 2012;35:182–184.
35. Chen HL, Hsiao FY. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study. Pharmacoepidemiol Drug Saf 2015;24:841–848.
36. Ou LB, Moriello C, Douros A, Filion KB. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2021;87:3649–3658.
37. Song CW, Chun HJ, Kim CD, Ryu HS, Choe JG, Hyun JH. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med 1998;13:15–21.
38. Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000;14:561–569.
39. Melga P, Mansi C, Ciuchi E, Giusti R, Sciaba L, Prando R. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care 1997;20:55–58.
40. Corazza GR, Biagi F, Albano O, et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol 1996;28:317–323.
41. Mearin F, Rodrigo L, Pérez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004;2:301–308.
42. Lozano R, Concha MP, Montealegre A, et al. Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Ther Clin Risk Manag 2007;3:149–155.
43. Mansi C, Savarino V, Vigneri S, et al. Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study. Aliment Pharmacol Ther 1995;9:185–189.
44. Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders. Mov Disord 2009;24:2249–2253.
45. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832–840.
46. Matsumoto K, Kimura H, Tashima K, Uchida M, Horie S. Validation of 13C-acetic acid breath test by measuring effects of loperamide, morphine, mosapride, and itopride on gastric emptying in mice. Biol Pharm Bull 2008;31:1917–1922.
47. Choung RS, Talley NJ, Peterson J, et al. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007;19:180–187.
48. Van den Houte K, Carbone F, Pauwels A, Vos R, Vanuytsel T, Tack J. Influence of itopride and domperidone on gastric tone and on the perception of gastric distention in healthy subjects. Neurogastroenterol Motil 2019;31e13544.
49. Scarpellini E, Vos R, Blondeau K, et al. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther 2011;33:99–105.
50. Katagiri F, Shiga T, Inoue S, Sato Y, Itoh H, Takeyama M. Effects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects. Pharmacology 2006;77:115–121.
51. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740–746.
52. Kamiya T, Shikano M, Kubota E, et al. A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan: the Nagoya study. J Clin Biochem Nutr 2017;60:130–135.
53. Carbone F, Vandenberghe A, Holvoet L, et al. A double-blind randomized, multicenter, placebo-controlled study of itopride in functional dyspepsia postprandial distress syndrome. Neurogastroenterol Motil 2022;doi: 10.1111/nmo.14337. [Epub ahead of print].
54. Stevens JE, Russo A, Maddox AF, et al. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil 2008;20:456–463.
55. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005;11:4210–4214.
56. Chun BJ, Lee DS. The effect of itopride combined with lansoprazole in patients with laryngopharyngeal reflux disease. Eur Arch Otorhinolaryngol 2013;270:1385–1390.
57. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013;20:14–21.
58. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99–112.
59. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008;68:981–991.
60. Choi HS, Kim EJ, Kim MS, et al. Effect of combination therapy of oral famotidine with mosapride on intragastric pH and gastric emptying in rats. Korean J Helicobacter Up Gastrointest Res 2021;21:220–225.
61. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682–686.
62. Kessing BF, Smout AJ, Bennink RJ, Kraaijpoel N, Oors JM, Bredenoord AJ. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil 2014;26:1079–1086.
63. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354–360.
64. Carbone F, Vanuytsel T, Tack J. The effect of prucalopride on gastric sensorimotor function and satiation in healthy volunteers. Neurogastroenterol Motil 2021;33e14083.
65. Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959–967.
66. Ji SW, Park H, Lee PR, Lee OY, Kim DK. Effects of mosapride on upper gastrointestinal symptoms and gastric emptying in patients with functional dyspepsia. Korean J Gastrointest Motil 2004;10:27–34.
67. Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005;21 Suppl 2:37–41.
68. Hongo M, Harasawa S, Mine T, et al. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol 2012;27:62–68.
69. Sakurai K, Nagahara A, Inoue K, et al. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol 2012;12:42.
70. Kawamura E, Enomoto M, Kotani K, et al. Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis. Dig Dis Sci 2012;57:1510–1516.
71. Wei W, Ge ZZ, Lu H, Gao YJ, Hu YB, Xiao SD. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007;22:1605–1608.
72. Narita K, Tsunoda A, Takenaka K, Watanabe M, Nakao K, Kusano M. Effect of mosapride on recovery of intestinal motility after hand-assisted laparoscopic colectomy for carcinoma. Dis Colon Rectum 2008;51:1692–1695.
73. Toyomasu Y, Mochiki E, Morita H, et al. Mosapride citrate improves postoperative ileus of patients with colectomy. J Gastrointest Surg 2011;15:1361–1367.
74. Lim HC, Kim JH, Youn YH, Lee EH, Lee BK, Park H. Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study. J Neurogastroenterol Motil 2013;19:495–502.
75. Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;33:323–332.
76. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20:680–686.
77. Ueno N, Inui A, Satoh Y. The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res Clin Pract 2010;87:27–32.
78. Maruoka D, Arai M, Tanaka T, et al. Mosapride citrate increases postprandial glucagon-like peptide-1, insulin, and gene expression of sweet taste receptors. Dig Dis Sci 2015;60:345–353.
79. Nam JS, Nam JY, Yoo JS, et al. The effect of mosapride (5HT-4 receptor agonist) on insulin sensitivity and GLUT4 translocation. Diabetes Res Clin Pract 2010;87:329–334.
80. Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003;61:175–182.
81. Ueno N, Inui A, Asakawa A, et al. Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with type II diabetes mellitus. Diabetologia 2002;45:792–797.
82. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344–2354.
83. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315–328.
84. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357–365.
85. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999–e541.
86. Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32:1113–1123.
87. Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22:991–998. e255.
88. Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol 2015;110:741–748.
89. Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil 2015;27:805–815.
90. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol 2019;114:1265–1274.
91. Andrews CN, Woo M, Buresi M, et al. Prucalopride in diabetic and connective tissue disease-related gastroparesis: randomized placebo-controlled crossover pilot trial. Neurogastroenterol Motil 2021;33e13958.
92. Carbone F, Van den Houte K, Goelen N, et al. Mechanism underlying symptom benefit with prucalopride in gastroparesis. Am J Gastroenterol 2019;114:1920–1921.
93. Jandee S, Wetwittayakhlang P, Boonsri P. Efficacy of prucalopride in critically ill patients with paralytic ileus: a pilot randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol 2021;36:362–366.
94. Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012;35:48–55.
95. Yeon SE, Kim SY, Chung WC, et al. Safety/efficacy of prucalopride in Korean patients with chronic constipation: post-marketing surveillance. Korean J Gastroenterol 2021;78:219–226.
96. Gilsenan A, Fortuny J, Cainzos-Achirica M, et al. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf 2019;42:1179–1190.
97. Kim YS, Kim JW, Ha NY, Kim J, Ryu HS. Herbal therapies in functional gastrointestinal disorders: a narrative review and clinical implication. Front Psychiatry 2020;11:601.
98. Shin CM, Lee YJ, Kim JM, et al. DA-9701 on gastric motility in patients with Parkinson's disease: a randomized controlled trial. Parkinsonism Relat Disord 2018;54:84–89.
99. Kim YS, Lee MY, Park JS, et al. Effect of DA-9701 on feeding inhibition induced by acute restraint stress in rats. Korean J Helicobacter Up Gastrointest Res 2018;18:50–55.
100. Choi MG, Rhee PL, Park H, et al. Randomized, controlled, multi-center trial: comparing the safety and efficacy of DA-9701 and itopride hydrochloride in patients with functional dyspepsia. J Neurogastroenterol Motil 2015;21:414–422.
101. Jung HK, Lee KJ, Choi MG, et al. Efficacy of DA-9701 (motilitone) in functional dyspepsia compared to pantoprazole: a multicenter, randomized, double-blind, non-inferiority study. J Neurogastroenterol Motil 2016;22:254–263.
102. Park JY, Kim JG, Hong SJ, et al. A randomized double-blind comparative study of the efficacy of Helicobacter pylori eradication therapy and Motilitone® for functional dyspepsia. Korean J Helicobacter Up Gastrointest Res 2019;19:106–114.
103. Park CH, Kim HS, Lee SK. Effects of the new prokinetic agent DA-9701 formulated with corydalis tuber and pharbitis seed in patients with minimal change esophagitis: a bicenter, randomized, double blind, placebo-controlled study. J Neurogastroenterol Motil 2014;20:338–346.
104. Kim SY, Woo HS, Kim KO, et al. DA-9701 improves colonic transit time and symptoms in patients with functional constipation: a prospective study. J Gastroenterol Hepatol 2017;32:1943–1948.
105. Lee JY, Kim N, Yoon H, Shin CM, Park YS, Lee DH. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of DA-9701 (motilitone) in patients with constipation-type irritable bowel syndrome and functional dyspepsia overlap: a pilot study. J Neurogastroenterol Motil 2022;28:265–275.
106. Deloose E, Verbeure W, Depoortere I, Tack J. Motilin: from gastric motility stimulation to hunger signalling. Nat Rev Endocrinol 2019;15:238–250.
107. Camilleri M, Atieh J. New developments in prokinetic therapy for gastric motility disorders. Front Pharmacol 2021;12:711500.
108. Lee MY, Choi SC, Kim YS. The role of gut microbiota and use of probiotics in the treatment of upper gastrointestinal diseases. Korean J Helicobacter Up Gastrointest Res 2019;19:99–105.
109. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983;98:86–95.
110. Martres MP, Sokoloff P, Schwartz JC. Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotides. Naunyn Schmiedebergs Arch Pharmacol 1984;325:116–123.
111. Pero RW, Olsson A, Simanaitis M, Amiri A, Andersen I. Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide. Pharmacol Toxicol 1997;80:231–239.
112. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264–270.
113. Sokoloff P, Andrieux M, Besançon R, et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 1992;225:331–337.
114. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264–270.
115. Kilpatrick GJ, el Tayar N, Van de Waterbeemd H, Jenner P, Testa B, Marsden CD. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Mol Pharmacol 1986;30:226–234.
116. Tonini M. Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996;33:217–226.
117. Coley C, Woodward R, Johansson AM, Strange PG, Naylor LH. Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding. J Neurochem 2000;74:358–366.
118. Tonini M, De Giorgio R, Spelta V, et al. 5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract. Dig Liver Dis 2003;35:244–250.